SCHEMBL3926542

SCHEMBL3926542

CC(=O)OCC(=O)NC(Sc1ncccc1C(=O)Nc1cccc(C(F)(F)F)c1)c1ccncc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.50
FLT1 P17948 4/20 0.50
ABL1 P00519 1/20 0.50
EGFR P00533 1/20 0.50
CSF1R P07333 1/20 0.50
PDGFRB P09619 1/20 0.50
KIT P10721 1/20 0.50
FLT4 P35916 1/20 0.50
RXFP1 Q9HBX9 5/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
LMNA P02545 2/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3924825 0.93 KDR (0.52) KDRFLT1ABL1EGFRCSF1R
SCHEMBL1941840 0.89 KMT2A (0.43) KDRFLT1MEN1KMT2ALMNA
SCHEMBL3932283 0.89 KDR (0.43) KDRKMT2ALMNAALDH1A1NPSR1
SCHEMBL1941558 0.88 RXFP1 (0.50) KDRFLT1ABL1EGFRCSF1R
SCHEMBL3932858 0.88 RXFP1 (0.51) KDRFLT1ABL1EGFRCSF1R
SCHEMBL1942085 0.87 RXFP1 (0.47) KDRFLT1ABL1EGFRCSF1R
SCHEMBL3927552 0.86 KMT2A (0.45) KDRFLT1KMT2A
SCHEMBL1941540 0.86 KMT2A (0.44) KDRMEN1KMT2ALMNAALDH1A1
SCHEMBL1941150 0.85 KDR (0.55) KDRFLT1ABL1KMT2AALDH1A1
SCHEMBL1942408 0.85 KDR (0.42) KDRFLT1CSF1RKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544703-B2 Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-06-09 US disclosed
US-20070149574-A1 Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein SANTEN PHARMACEUTICAL CO., LTD. (JP) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149574-A1 Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein FLT4, FLT1, TIE1 KDR 12/4885FLT1 2/4885ABL1 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.